6041-29-8

Basic information

• Product Name: 1-amino-N-[3-(cyclohexylmethylamino)propyl]-9,10-dihydro-4-(methylamino)-9,10-dioxoanthracene-2-carboxamide
• Synonyms: 1-amino-N-[3-(cyclohexylmethylamino)propyl]-9,10-dihydro-4-(methylamino)-9,10-dioxoanthracene-2-carboxamide;1-Amino-N-[3-[cyclohexyl(methyl)amino]propyl]-9,10-dihydro-4-(methylamino)-9,10-dioxo-2-anthracenecarboxamide;1-Amino-N-(3-(cyclohexylmethylamino)propyl)-9,10-dihydro-4-(methylamino)-9,10-dioxoanthracene-2-carboxamide;2-Anthracenecarboxamide, 1-amino-N-(3-(cyclohexylmethylamino)propyl)-9,10-dihydro-4-(methylamino)-9,10-dioxo-;Einecs 227-929-6
• CAS NO: 6041-29-8
• Molecular Formula: C₂₆H₃₂N₄O₃
• Molecular Weight: 448.55728
• EINECS: 227-929-6
• Mol File: 6041-29-8.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 658°C at 760 mmHg
• Flash Point: 351.7°C
• Appearance: /
• Density: 1.26g/cm³
• Vapor Pressure: 3.45E-17mmHg at 25°C
• Refractive Index: 1.637
• CAS DataBase Reference: 1-amino-N-[3-(cyclohexylmethylamino)propyl]-9,10-dihydro-4-(methylamino)-9,10-dioxoanthracene-2-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 1-amino-N-[3-(cyclohexylmethylamino)propyl]-9,10-dihydro-4-(methylamino)-9,10-dioxoanthracene-2-carboxamide(6041-29-8)
• EPA Substance Registry System: 1-amino-N-[3-(cyclohexylmethylamino)propyl]-9,10-dihydro-4-(methylamino)-9,10-dioxoanthracene-2-carboxamide(6041-29-8)

Safety Data

• Hazardous Substances Data: 6041-29-8(Hazardous Substances Data)

Usage

Purpose

Chemotherapy drug
Used in the treatment of various types of cancer, including leukemia, multiple myeloma, and certain types of solid tumors.

Mechanism of action

Inhibits the growth and replication of cancer cells
Works by intercalating DNA, causing breaks in the DNA strands of cancer cells and preventing their further proliferation.

Administration

Intravenous injection

Side effects

Serious risks of toxic side effects
Damage to the heart and bone marrow

Patient care

Close monitoring and management of potential complications required during treatment
Patients receiving this drug need to be closely monitored for potential side effects and complications.

InChI:InChI=1/C26H32N4O3/c1-28-20-15-19(26(27)33)23(29-13-8-14-30(2)16-9-4-3-5-10-16)22-21(20)24(31)17-11-6-7-12-18(17)25(22)32/h6-7,11-12,15-16,28-29H,3-5,8-10,13-14H2,1-2H3,(H2,27,33)